Vimta Labs Ltd. - Quarterly/Annual Result Disclosures and Notes dated 30 Jun 2023

Notes to the results :
1.The above unaudited standalone financial results for the quarter ended June 30, 2023 have been reviewed
and recommended by the Audit Committee and approved by the Board in its meeting held on July 28, 2023.
2.The results for the quarter ended June 30, 2023 were subjected to "Limited Review" by the statutory auditors of the
company. An unmodified report was issued by them thereon.
3.These unaudited standalone financials results of the Company are prepared in accordance with the Indian
Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 ("the Act") read
with relevant rules issued thereunder and other accounting principles generally accepted in India and the
guidelines issued by the Securities and Exchange Board of India ("SEBI") in this regard.
4.The management has identified the reportable segments in accordance with the requirements of Ind AS-
108 'Operating Segments', and decided that the Company has only one reportable segment, viz. 'Contract
Research and Testing Services'.
5.The company has entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards
Authority of India (FSSAI) on June 29, 2021 to setup, operate and transfer (SOT) a National food Testing
Laboratory (NFL) in JNPT,Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has
been considered as a "Service Concessionaire Arrangement" (SCA) and accordingly, revenue and costs are
allocatable between those relating to lab setup services and those relating to operation and maintenance
services. Further, the Company has acquired the right to charge the customer for the services to be
rendered which has been assessed as an intangible asset.
Consequently, the amount of revenues from operations and lab setup expenses includes Rs 1.95 million for
the quarter ended June 30, 2023, Rs 0.66 million for the quarter ended March 31, 2023, Rs 3.31 million for the
quarter ended June 30, 2022, and Rs 19.86 million for year ended March 31, 2023, respectively representing
the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the
right to charge the customer for the services to be rendered, respectively.
6.Pursuant to ' Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021)', during the quarter ended , the
company has allotted 9,560 Equity shares of Rs 2 each upon exercise of Employee stock options by the
eligible employees . Accordingly, the paid up share capital of the company stands increased from Rs44.26
million to Rs44.28 million for the period ended 31st March,2023 to 30th June ,2023 respectively.
In respect of stock options granted pursuant to the Company’s stock options plan, the fair value of the
options is accounted as employee compensation expense over the vesting period. Consequently, the
amount of employee benefits expense includes Rs 4.58 million for the quarter ended June 30,2023, Rs 5.35
million for the quarter ended March 31,2023, Rs 13.58 million for the quarter ended June 30,2022 and Rs 40.74
million for year ended March 31, 2023 respectively.
7.The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.